openPR Logo
Press release

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019

03-19-2019 04:07 PM CET | Health & Medicine

Press release from: ISA Pharmaceuticals

/ PR Agency: akampion
- Recognition for outstanding and innovative cancer research

Leiden, The Netherlands, March 19, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019 from the American Association of Cancer Research (AACR) and the Cancer Research Institute.

The AACR-CRI Lloyd J. Old Award in Cancer Immunology recognizes an active scientist whose outstanding and innovative research has had a major impact on the cancer field and has the potential to stimulate new directions in cancer immunology.

The award was established in honor of the late Lloyd J. Old, MD, who is considered the “Founding Father of Modern Tumor Immunology.” Dr. Old’s outstanding research in the field of cancer immunology as well as his leadership in fostering the field has had a far-reaching impact on cancer research and treatment.

Prof. Melief will deliver his award lecture titled "Adventures in Cancer Immunotherapy" at the AACR Annual Meeting 2019 in Atlanta, GA, USA, on April 2, 2019.

Prof. Melief is a pioneer of translational cancer immunotherapy research. In addition to his role as Chief Scientific Officer at ISA Pharmaceuticals, Prof. Melief is Emeritus Professor of Tumor Immunology at the Leiden University Medical Center, Netherlands. Prof. Melief is a member of the Royal Netherlands Academy of Arts and Sciences, author of more than 530 peer-reviewed publications and inventor on more than 30 patents and patent applications. In addition, he is a member of the Cancer Research Institute’s Scientific Advisory Council, a member of CRI’s global clinical investigator network and serves on the CLIP Grant Review Committee. Moreover, he serves as Chairman of the Scientific Advisory Board of TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University, Mainz, Germany.

Prof. Melief´s work focuses on the development of effective immunotherapies for virus-induced tumors. To this end, he has established a novel vaccine concept based on synthetic long peptides (SLP) for the treatment of cancer patients. Among others, Prof. Melief and his team have demonstrated the clinical effectiveness of these therapeutic vaccines in patients with pre-malignant lesions caused by Human Papilloma Virus type 16 (HPV-16). In addition, Prof. Melief and his team showed that a combination of SLP vaccination and standard chemotherapy strengthened the immune response of cervical cancer patients and prolonged their survival. The researchers further discovered that a similar effect could be achieved in patients with HPV-related head and neck cancer by administering the vaccines in conjunction with checkpoint inhibitor therapy.

“All of us at ISA Pharmaceuticals are very proud that AACR and CRI recognize the great achievements of our CSO Prof. Kees Melief,” said Gerben Moolhuizen, CEO of ISA Pharmaceuticals. “His pioneering work has the potential to significantly improve the treatment of cancer and chronic infections and has led to the development of ISA´s proprietary SLP® technology, which forms the basis of ISA´s targeted immune activation therapeutics. SLP-based products already demonstrated clinical proof-of-concept in patients with pre-cancerous disease and have also shown potential to improve the outcome for patients with advanced cancer. Currently, ISA´s lead SLP compound ISA101 is being tested in randomized late-stage clinical trials in advanced cancer patients. We at ISA are looking forward to bringing these innovative targeted therapies to patients.”

###

About ISA Pharmaceuticals

ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body’s own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP® lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810, Libtayo®), a PD-1 (programmed cell death protein 1) antibody in development by Regeneron, which was recently approved by the FDA as monotherapy for patients with advanced cutaneous squamous cell carcinoma. ISA develops a diverse SLP® immunotherapy portfolio based on different disease-related antigens in order to provide novel treatment options for orphan and larger unmet cancer indications.

For more information, please visit www.isa-pharma.com.

SLP® and AMPLIVANT® are registered trademarks in Europe.

Miranda Molenaar
ISA Pharmaceuticals
J.H. Oortweg 19
2333 CH Leiden
The Netherlands
+31 71 332 2310

Contact & Media Inquiries:
akampion
Dr. Ludger Wess Ines-Regina Buth
Managing Partner Managing Partner
Tel. +49 40 88 16 59 64 Tel. +49 30 23 63 27 68
info(at)akampion.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019 here

News-ID: 1661372 • Views: 224

More Releases from ISA Pharmaceuticals

ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeti …
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation Leiden, The Netherlands, March 28, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will give an oral presentation at the upcoming AACR Annual Meeting 2019 in Atlanta, GA, USA, on March 31, 2019. The presentation titled "A strong HPV-specific T-cell response after chemo-immunotherapy for advanced
ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and …
- ISA101b and Cemiplimab studied in patients with platinum refractory HPV16-positive oropharyngeal cancer (OPC) Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals B.V., a clinical-stage company dedicated to the development of rationally designed immunotherapeutics, today announced randomization of the first patient in a Phase 2 combination trial of its lead compound ISA101b and Regeneron´s (NASDAQ: REGN) anti-PD-1 antibody cemiplimab (REGN2810). This double blind, placebo-controlled, randomized, phase 2 study (NCT03669718)
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief to Present …
Leiden, The Netherlands, January 16, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief will give a talk at the upcoming Keystone Cancer Vaccines Conference in Vancouver, BC, Canada, January 20-24, 2019. The talk titled "Therapeutic HPV16 Vaccination Is Effective as Monotherapy in Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced Cancers" is scheduled for Thursday, January 24, 2019, at 17:00
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Receives ES …
Leiden, The Netherlands, November 13, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief has been selected by the European Society for Medical Oncology (ESMO) to receive the 2018 ESMO Immuno-Oncology Award in recognition of his life’s work in studying the interactions of the immune system with cancer. He will receive the award during an official ceremony at the opening

All 5 Releases


More Releases for Prof

Ear Ringing How to Treat by Prof. Dr. Luis Gavin
By Prof. Dr. Luis Gavin, King’s College and Gargash Hospital in Dubai Professor Dr. Luis Gavin – a leading international Speaker, Maxillofacial Surgeon from Spain, Specialist in ear ringing and tinnitus, dealing with hundreds of patients each year. Ear ringing is the perception of noise or ringing in the ears. It can cause hearing loss, loudness, discomfort and imbalance. Sadly, many cases often go untreated or are misdiagnosed as Meniere's disease, vertigo,
Face lifting Without Surgery By Prof. Dr. Luis Gavin
Face lifting Without Surgery By Prof. Dr. Luis Gavin, a leading international Speaker, Maxillofacial Surgery Consultant – and Ozone Therapist Works at King’s College Hospital, a leading hospital in Dubai. How Is it Performed? The thread lift procedure can be performed under local anesthesia and only takes 1 to 2 hours. The surgeon inserts tiny threads, bio absorbable sutures, under the skin of the face. The sutures attach to skin tissue and
Prof. Igor Eleferenko appointed Dean of Al-Khalifa Business School
H.E. Prof. Sir Igor Eleferenko Ph.D. (Russian Federation) has been elected on 6th April 2020 as the Dean of Al-Khalifa Business School. Born on 23rd May 1958, in Moscow; in 1980 he graduated from Moscow State Pedagogical Institute named after M. Teresa. He has more than 40 years of experience as Associate Editor, Editor, Deputy Head of the APN Bureau in Havana, Deputy Editor-in-Chief, Editor-in-Chief of AVID APN, Editor-in-chief of TRK "TV-News"
Union Budget 2020-21 : Forecasts by Prof. Yamini Agarwal
Fiscal Deficit in the Budget to be presented on 1st February, 2020 is likely to be 3.34% depending upon the growth targets fixed by the Finance Minister said Prof. (Dr.) Yamini Agarwal, Professor of Finance and Dean (Research), Indian Institute of Finance while making a presentation on "My Budget" for the programme - Mera Budget on Rajya Sabha TV recently. According to her, the major issues in the present budget are
Banasthali Celebrates 87th Birthday of Dada Prof Diwakar Shastri
By nurturing Banasthali which is today one among the most sought after and top ranking women’s universities in India with global ranking, Prof Diwakar Shastri known to one and all as “Dada” built capacities for the spirit of inquiry, creativity and moral leadership among the enrolled girl students and became their role models. Known for his dignified unassuming personality, gleaming intellect, meticulous planning, deep regard for punctuality, far reaching vision and
Prof Joy Mukhopadhyay Talks on Colour Science & Technology at Banasthali
One field which combines Chemistry, Physics, Physiology and Psychology is undoubtedly Colour Science and Technology. Global market size of dyes and pigments is of the order of USD 27.8 Billion with India market size of USD 4.9 Billion. Specialty chemicals, which comprise low volume, high value chemicals with specific applications, constitute a significant part of the Indian chemical industry include agrochemicals, flavors and fragrances, surfactants, polymer additives, personal care ingredients,